Michael A. Narachi
2011
In 2011, Michael A. Narachi earned a total compensation of $5.8M as President, Chief Executive Officer and Member of the Board of Directors at Orexigen Therapeutics, a 86% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $398,438 |
|---|---|
| Option Awards | $4,734,704 |
| Salary | $625,000 |
| Other | $7,626 |
| Total | $5,765,768 |
Narachi received $4.7M in option awards, accounting for 82% of the total pay in 2011.
Narachi also received $398.4K in non-equity incentive plan, $625K in salary and $7.6K in other compensation.
Rankings
In 2011, Michael A. Narachi's compensation ranked 870th out of 10,747 executives tracked by ExecPay. In other words, Narachi earned more than 91.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 870 out of 10,747 | 92nd |
Division Manufacturing | 321 out of 3,960 | 92nd |
Major group Chemicals And Allied Products | 74 out of 1,033 | 93rd |
Industry group Drugs | 40 out of 781 | 95th |
Industry Pharmaceutical Preparations | 35 out of 571 | 94th |
Source: SEC filing on April 30, 2014.
Narachi's colleagues
We found five more compensation records of executives who worked with Michael A. Narachi at Orexigen Therapeutics in 2011.
2011
Heather Turner
Orexigen Therapeutics
General Counsel
2011
Preston Klassen
Orexigen Therapeutics
Head of Global NB32 Program and Senior Vice President, Product Development
2011
Joseph Hagan
Orexigen Therapeutics
Chief Business Officer
2011
Mark Booth
Orexigen Therapeutics
Chief Commercial Officer
2011
Graham Cooper
Orexigen Therapeutics